Inhibition of SIRT2 Promotes APP Acetylation and Ameliorates Cognitive Impairment in APP/PS1 Transgenic Mice.
Ning Bai,Na Li,Rong Cheng,Yi Guan,Xiong Zhao,Zhijie Song,Hongde Xu,Fei Yi,Bo Jiang,Xiaoman Li,Xuan Wu,Cui Jiang,Tingting Zhou,Qiqiang Guo,Wendong Guo,Yanling Feng,Zhuo Wang,Mengtao Ma,Yang Yu,Zhanyou Wang,Shengping Zhang,Chuangui Wang,Weidong Zhao,Shihui Liu,Xiaoyu Song,Hua Liu,Liu Cao
DOI: https://doi.org/10.1016/j.celrep.2022.111062
IF: 8.8
2022-01-01
Cell Reports
Abstract:Aging is a primary risk factor for neurodegenerative diseases, such as Alzheimer's disease (AD). SIRT2, an NAD+(nicotinamide adenine dinucleotide)-dependent deacetylase, accumulates in the aging brain. Here, we report that, in the amyloid precursor protein (APP)/PS1 transgenic mouse model of AD, genetic deletion of SIRT2 or pharmacological inhibition of SIRT2 ameliorates cognitive impairment. We find that suppression of SIRT2 enhances acetylation of APP, which promotes non-amyloidogenic processing of APP at the cell surface, leading to increased soluble APP-α (sAPPα). We discover that lysines 132 and 134 of the major pathogenic protein β-amyloid (Aβ) precursor are acetylated and that these residues are deacetylated by SIRT2. Strikingly, exogenous expression of wild-type or an acetylation-mimic APP mutant protects cultured primary neurons from Aβ42 challenge. Our study identifies SIRT2-mediated deacetylation of APP on K132 and K134 as a regulated post-translational modification (PTM) and suggests inhibition of SIRT2 as a potential therapeutic strategy for AD.